• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.

作者信息

Goemans B F, Zwaan C M, Vijverberg S J H, Loonen A H, Creutzig U, Hählen K, Reinhardt D, Gibson B E S, Cloos J, Kaspers G J L

出版信息

Leukemia. 2008 Dec;22(12):2284-5. doi: 10.1038/leu.2008.147. Epub 2008 Jun 19.

DOI:10.1038/leu.2008.147
PMID:18563175
Abstract
摘要

相似文献

1
Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.
Leukemia. 2008 Dec;22(12):2284-5. doi: 10.1038/leu.2008.147. Epub 2008 Jun 19.
2
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.批准摘要：吉妥珠单抗奥唑米星用于复发急性髓系白血病
Clin Cancer Res. 2001 Jun;7(6):1490-6.
3
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.Bak和Bax的激活不足赋予急性髓系白血病（AML）对吉妥珠单抗奥唑米星诱导的凋亡性细胞死亡的抗性。
Exp Hematol. 2009 Jun;37(6):755-66. doi: 10.1016/j.exphem.2009.03.002.
4
Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.吉妥单抗奥唑米星（麦罗塔）在急性髓系白血病中的细胞毒性活性与蛋白激酶Syk的表达相关。
Leukemia. 2006 Dec;20(12):2093-101. doi: 10.1038/sj.leu.2404437. Epub 2006 Oct 19.
5
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.AKT 信号转导作为一个与人类 AML 细胞对吉妥珠单抗奥佐米星体外耐药相关的新的因素。
PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.
6
[Antibody directed therapy for leukemia].[白血病的抗体导向治疗]
Nihon Rinsho. 2002 Mar;60(3):517-24.
7
[The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].[吉妥珠单抗奥唑米星在急性髓系白血病患者治疗中的作用]
Gan To Kagaku Ryoho. 2008 Sep;35(9):1629-34.
8
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.分析影响急性髓系白血病白血病干/祖细胞对吉妥珠单抗奥唑米星（商品名：Mylotarg）体外化疗敏感性的因素。
Leukemia. 2010 Jan;24(1):74-80. doi: 10.1038/leu.2009.199. Epub 2009 Sep 24.
9
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.吉妥单抗奥唑米星治疗急性髓系白血病。
Cancer Treat Rev. 2008 Feb;34(1):49-60. doi: 10.1016/j.ctrv.2007.09.001. Epub 2007 Oct 17.
10
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].[老年难治性急性髓系白血病患者接受吉妥珠单抗奥唑米星单药治疗后长期完全缓解]
Gan To Kagaku Ryoho. 2007 Nov;34(11):1881-3.

引用本文的文献

1
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group.DNA损伤反应药物基因组学（DDR_PGx）评分可预测儿童急性髓系白血病（AML）中由吉妥珠单抗奥唑米星组成的化疗方案的疗效：来自儿童肿瘤学组的报告。
Clin Cancer Res. 2025 Mar 3;31(5):890-898. doi: 10.1158/1078-0432.CCR-23-2073.
2
Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.治疗儿童患者中CD33阳性初发急性髓系白血病：聚焦吉妥珠单抗奥唑米星的临床价值
Onco Targets Ther. 2023 Apr 29;16:297-308. doi: 10.2147/OTT.S263829. eCollection 2023.
3
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
吉妥珠单抗奥唑米星对急性髓系白血病的治疗靶向作用
Cancers (Basel). 2021 Sep 11;13(18):4566. doi: 10.3390/cancers13184566.
4
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin.CD33表达与吉妥珠单抗奥唑米星在急性髓系白血病中的作用：同一枚硬币的两面
Cancers (Basel). 2021 Jun 28;13(13):3214. doi: 10.3390/cancers13133214.
5
Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series.吉妥珠单抗奥唑米星在造血细胞移植前对复发/难治性急性白血病实现完全缓解有效：病例系列
Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):532-536. doi: 10.1016/j.htct.2020.07.008. Epub 2020 Sep 13.
6
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.ABCB1 SNP 预测吉妥珠单抗奥佐米星治疗急性髓系白血病患者的结局：来自儿童肿瘤学组 AAML0531 试验的报告。
Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y.
7
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.吉妥珠单抗奥佐米星治疗新诊断的 CD33 阳性急性髓系白血病。
Future Oncol. 2018 Dec;14(30):3199-3213. doi: 10.2217/fon-2018-0325. Epub 2018 Jul 24.
8
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.吉妥珠单抗奥佐米星治疗急性髓系白血病。
Expert Rev Clin Pharmacol. 2018 Jun;11(6):549-559. doi: 10.1080/17512433.2018.1478725. Epub 2018 Jun 11.
9
Gemtuzumab ozogamicin in acute myeloid leukemia.吉妥珠单抗奥佐米星治疗急性髓细胞白血病。
Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13.
10
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.吉妥珠单抗奥佐米星治疗急性髓细胞白血病的抗体疗法。
Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1311-34. doi: 10.2741/4181.